Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 31, 2002

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions
Warts
Interventions
DRUG

Imiquimod 5% cream

Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.

Trial Locations (18)

B-1000

Départment de Gynécologie-Obstétrique CHU Saint-Pierre, Brussels

Service de Dermatologie CHU Saint-Pierre, Brussels

Service Dermatologie C.H. François Rabelais (César de Paepe), Brussels

B-1070

Service de Dermatologie Hôpital Erasme, Brussels

F-25030

Service de Dermatologie et Vénéréologie Hôpital Saint Jacques, Besançon

F-33800

Cabinet Médical, Bordeaux

F-92100

Service de Dermatologie, Hôpital Ambroise Paré, Boulogne-Billancourt

F-13005

Service de Maladies Infectieuses Hôpital de la Conception, Marseille

F-44000

Service de Dermatologie Hôtel Dieu, Nantes

F-06202

Service de Dermatologie Hôpital de l'Archet II, Nice

F-75006

Service Dermatologie Hopital COCHIN - Pavillon Tarnier, Paris

F-75011

Cabinet Médical, Paris

F-75014

Institut Alfred Fournier, Paris

F-75015

Cabinet Médical, Paris

F-75018

Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard, Paris

F-75020

Service de Dermatologie Hopital Tenon, Paris

F-31052

Service de Dermatologie Groupe Hospitalier La Grave, Toulouse

F-26000

Service de Dermatologie Centre Hospitalier de Valence, Valence

All Listed Sponsors
collaborator

ORION Sante

UNKNOWN

lead

MEDA Pharma GmbH & Co. KG

INDUSTRY

NCT00761371 - Imiquimod 5% Cream in the Treatment of External Genital or Perianal Warts in HIV+ Patients | Biotech Hunter | Biotech Hunter